scholarly journals The role of FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma

2014 ◽  
Vol 168 (6) ◽  
pp. 845-853 ◽  
Author(s):  
Deepa Bhojwani ◽  
Mary B. McCarville ◽  
John K. Choi ◽  
Jennifer Sawyer ◽  
Monika L. Metzger ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Residual Disease ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct

Postchemotherapy Histiocyte-Rich Pseudotumor of the Spleen Simulating Residual Disease in a Patient With Non-Hodgkin Lymphoma on FDG PET/CT

2019 ◽  
Vol 44 (6) ◽  
pp. e409-e412
Author(s):  
Nir Hod ◽  
Sophie Lantsberg ◽  
Reut Anconina ◽  
Daniel Levin ◽  
Karen Nalbandyan ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Residual Disease ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals FDG-PET/CT for the Management of Post-Chemotherapy Residual Mass in Hodgkin lymphoma

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 3952
Author(s):  
Andrea Gallamini ◽  
Michał Kurlapski ◽  
Jan Maciej Zaucha
Keyword(s):  
Treatment Outcome ◽  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Quantitative Methods ◽  
Present Review ◽  
Response To Treatment ◽  
Published Evidence ◽  
Pet Ct ◽  
Fdg Pet Ct

In the present review, the authors report the published evidence on the use of functional imaging with FDG-PET/CT in assessing the final response to treatment in Hodgkin lymphoma. Despite a very high overall Negative Predictive Value of post-chemotherapy PET on treatment outcome ranging from 94% to 86%, according to different treatment intensity, the Positive Predicting Value proved much lower (40–25%). In the present review the Authors discuss the role of PET to guide consolidation RT over a RM after different chemotherapy regimens, both in early and in advanced-stage disease. A particular emphasis is dedicated to the peculiar issue of the qualitative versus semi-quantitative methods for End-of Therapy PET scan interpretation. A short hint will be given on the role of FDG-PET to assess the treatment outcome after immune checkpoint inhibitors.

scholarly journals FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

2021 ◽  
Author(s):  
Dominic Kaddu-Mulindwa ◽  
Bettina Altmann ◽  
Gerhard Held ◽  
Stephanie Angel ◽  
Stephan Stilgenbauer ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Predictive Value ◽  
Fdg Pet ◽  
Bone Marrow Involvement ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Initial Staging

Abstract Purpose Fluorine-18 fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG PET/CT) is the standard for staging aggressive non-Hodgkin lymphoma (NHL). Limited data from prospective studies is available to determine whether initial staging by FDG PET/CT provides treatment-relevant information of bone marrow (BM) involvement (BMI) and thus could spare BM biopsy (BMB). Methods Patients from PETAL (NCT00554164) and OPTIMAL>60 (NCT01478542) with aggressive B-cell NHL initially staged by FDG PET/CT and BMB were included in this pooled analysis. The reference standard to confirm BMI included a positive BMB and/or FDG PET/CT confirmed by targeted biopsy, complementary imaging (CT or magnetic resonance imaging), or concurrent disappearance of focal FDG-avid BM lesions with other lymphoma manifestations during immunochemotherapy. Results Among 930 patients, BMI was detected by BMB in 85 (prevalence 9%) and by FDG PET/CT in 185 (20%) cases, for a total of 221 cases (24%). All 185 PET-positive cases were true positive, and 709 of 745 PET-negative cases were true negative. For BMB and FDG PET/CT, sensitivity was 38% (95% confidence interval [CI]: 32–45%) and 84% (CI: 78–88%), specificity 100% (CI: 99–100%) and 100% (CI: 99–100%), positive predictive value 100% (CI: 96–100%) and 100% (CI: 98–100%), and negative predictive value 84% (CI: 81–86%) and 95% (CI: 93–97%), respectively. In all of the 36 PET-negative cases with confirmed BMI patients had other adverse factors according to IPI that precluded a change of standard treatment. Thus, the BMB would not have influenced the patient management. Conclusion In patients with aggressive B-cell NHL, routine BMB provides no critical staging information compared to FDG PET/CT and could therefore be omitted. Trial registration NCT00554164 and NCT01478542

scholarly journals Non-Hodgkin lymphoma of multiple extranodal involvement seen on MRI, FDG PET–CT scans

Medicine ◽  
2017 ◽  
Vol 96 (45) ◽  
pp. e8456 ◽  
Author(s):  
Shan Wang ◽  
Meng Meng ◽  
Qiuhu Wang ◽  
Kai Xu
Keyword(s):  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Ct Scans ◽  
Extranodal Involvement ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct

Role of FDG PET-CT in the treatment management of Hodgkin lymphoma

2018 ◽  
Vol 22 (5) ◽  
pp. 393-400 ◽  
Author(s):  
A. Berriolo-Riedinger ◽  
S. Becker ◽  
O. Casasnovas ◽  
T. Vander Borght ◽  
V. Édeline
Keyword(s):  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Treatment Management ◽  
Pet Ct ◽  
Fdg Pet Ct

Multiple Intraabdominal Purulent Collections Demonstrated on FDG PET/CT in Staging of Non-Hodgkin Lymphoma

2012 ◽  
Vol 37 (2) ◽  
pp. 210-213
Author(s):  
Jonathan Tow ◽  
Han Loh ◽  
Chuong Bui ◽  
Stephen Fuller ◽  
Robert Mansberg
Keyword(s):  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct

Utility of FDG-PET/CT in Follow-Up of Children Treated for Hodgkin and Non-Hodgkin Lymphoma

2006 ◽  
Vol 28 (5) ◽  
pp. 300-306 ◽  
Author(s):  
Melissa M. Rhodes ◽  
Dominique Delbeke ◽  
James A. Whitlock ◽  
William Martin ◽  
John F. Kuttesch ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct
Sign in / Sign up

Export Citation Format

Share Document